ANSWER: B

Rationale:

Incomplete cross-tolerance is the fundamental pharmacological principle underlying safe opioid rotation. When a patient is tolerant to one opioid, they are not fully cross-tolerant to another, because different opioids differ in intrinsic efficacy, receptor binding kinetics, and interactions with tolerance mechanisms. As a result, the equianalgesic dose of the new opioid is more potent relative to the patient's actual tolerance than it would be in an opioid-naive individual. The standard clinical approach is to reduce the calculated equianalgesic dose by 25–50% to account for this incomplete cross-tolerance, then titrate to effect.

• Option A: Option A is incorrect because half-life differences between opioids are not the reason for the standard cross-tolerance dose reduction; accumulation risk would be addressed by dosing interval adjustment, not a preemptive 40% reduction in the equianalgesic dose.
• Option C: Option C is incorrect because equianalgesic tables specifically account for route of administration — separate oral and parenteral equianalgesic values are listed, and the 3:1 oral-to-parenteral ratio for morphine is already incorporated into conversion calculations.
• Option D: Option D is incorrect as a primary rationale; while renal impairment is clinically relevant (it is actually the reason for the rotation in this case, given morphine-3-glucuronide and morphine-6-glucuronide accumulation), the dose reduction applied during opioid rotation is driven by the incomplete cross-tolerance principle, not solely by renal clearance of the new agent.
• Option E: Option E is incorrect; opioid tolerance is not complete and uniform — incomplete cross-tolerance is precisely the opposite of what Option E describes, and opioid-induced hyperalgesia (OIH) is a distinct phenomenon involving sensitization of pain pathways, not a consequence of uniform receptor-level tolerance.

ANSWER: A

Rationale:

The standard equianalgesic relationship for morphine is oral 30 mg ≈ intravenous (IV) or intramuscular (IM) 10 mg, representing a 3:1 oral-to-parenteral ratio. This ratio reflects the significant first-pass hepatic metabolism that morphine undergoes when absorbed from the gastrointestinal tract, reducing oral bioavailability to approximately 25–35%. Morphine is glucuronidated in the liver and gut wall to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) before reaching systemic circulation, meaning that a substantially larger oral dose is needed to achieve the same systemic morphine concentration as a given parenteral dose.

• Option B: Option B is incorrect because it inverts the relationship — parenteral morphine is more potent per milligram than oral morphine, not less, because the parenteral route bypasses first-pass metabolism entirely.
• Option C: Option C is incorrect because morphine does undergo clinically important first-pass metabolism; this is precisely why the oral dose must be approximately three times the parenteral dose to achieve equivalent analgesia.
• Option D: Option D is incorrect because the oral-to-parenteral ratio affects total dose equivalence — not merely onset speed — and is a well-established clinical reality that underlies all equianalgesic conversion calculations.
• Option E: Option E is incorrect because oral morphine bioavailability, while variable, is typically in the 25–35% range (not less than 20%), and the 6:1 ratio stated in Option E is not the accepted clinical standard; the 3:1 ratio is the reference used in practice and in standard equianalgesic tables.

ANSWER: D

Rationale:

The morphine-to-methadone equianalgesic ratio is uniquely dose-dependent, which distinguishes methadone from all other opioids and makes its conversion particularly complex and hazardous. At low prior morphine doses (below approximately 90 mg/day oral morphine equivalent), the ratio is roughly 4:1 (morphine:methadone), meaning approximately 4 mg of oral morphine is equivalent to 1 mg of methadone. At higher morphine doses — such as the 360 mg/day this patient is receiving — the ratio may be 12:1 or even higher, meaning that relatively small doses of methadone carry substantially more analgesic potency than a simple equianalgesic ratio would suggest. This non-linear relationship is thought to reflect receptor-level differences in partial tolerance, incomplete cross-tolerance, and methadone's NMDA receptor antagonism. At high prior morphine doses, underestimating this ratio by using the low-dose conversion table is a recognized cause of fatal methadone overdose following rotation.

• Option A: Option A is incorrect because the ratio is not fixed at 10:1 and is explicitly dose-dependent.
• Option B: Option B is incorrect because the 4:1 ratio applies only at low morphine doses; the claim that both agents act exclusively at the mu-opioid receptor is also incomplete — methadone is an NMDA receptor antagonist and has serotonergic properties as well.
• Option C: Option C is incorrect because methadone rotation in cancer pain is not universally contraindicated; it is an accepted practice when performed by clinicians experienced with its specific pharmacokinetics, using conservative dose estimates.
• Option E: Option E is incorrect because methadone and morphine are decidedly not equianalgesic on a milligram-per-milligram basis — methadone is substantially more potent per milligram, particularly at higher morphine dose equivalents.

ANSWER: E

Rationale:

Morphine undergoes glucuronidation to two principal metabolites: morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). M6G is a potent mu-opioid receptor agonist with analgesic and respiratory-depressant effects that may exceed those of the parent compound; M3G lacks significant opioid receptor affinity but is a neuroexcitatory compound that produces hyperalgesia, allodynia, myoclonus, and seizures through mechanisms that may involve glycine and NMDA receptor pathways. Both M3G and M6G are primarily eliminated by renal excretion; in renal failure, both metabolites accumulate to concentrations that can produce overt toxicity. The clinical picture of myoclonus, escalating pain (paradoxically, from M3G-induced hyperalgesia), and nausea in a patient with rising creatinine on long-term morphine is the classic presentation of glucuronide metabolite accumulation, and opioid rotation away from morphine is the appropriate management.

• Option A: Option A is incorrect because while protein binding changes in renal failure can affect opioid pharmacokinetics, this is not the primary mechanism of morphine toxicity in renal failure — metabolite accumulation is the dominant and clinically relevant mechanism.
• Option B: Option B is incorrect because morphine itself is not primarily renally eliminated — it is hepatically glucuronidated; it is the glucuronide metabolites that accumulate in renal failure, not the parent compound.
• Option C: Option C is incorrect because morphine is not a CYP3A4 substrate in the clinically relevant sense — it is glucuronidated by UDP-glucuronosyltransferases (UGT), not oxidized by the CYP system as the primary elimination pathway.
• Option D: Option D is incorrect because morphine absolutely does require dose adjustment and carries significant risk in renal impairment due to metabolite accumulation; hydromorphone also accumulates its neuroexcitatory metabolite hydromorphone-3-glucuronide (H3G) in renal failure and is not freely substitutable without caution.

ANSWER: E

Rationale:

The opioid-benzodiazepine interaction produces synergistic, not merely additive, respiratory depression through distinct and complementary pharmacodynamic mechanisms operating at different sites. Opioids, via mu-opioid receptor (MOR) activation in the medullary pre-Bötzinger complex and other brainstem respiratory centers, suppress the hypercapnic ventilatory drive — the fundamental reflex that increases respiratory rate and depth in response to rising carbon dioxide (CO₂). Benzodiazepines, via positive allosteric modulation of GABA-A (gamma-aminobutyric acid type A) receptors, increase the frequency of chloride channel opening throughout the CNS, including within brainstem respiratory control circuits, further depressing respiratory neuron activity. Because these two mechanisms act through independent molecular targets and pathways, their combined respiratory depression exceeds simple additivity — it is synergistic. This is why the combination was implicated in approximately 30% of prescription opioid overdose deaths before regulatory restrictions were introduced.

• Option A: Option A is incorrect because it falsely implies additivity rather than synergy and incorrectly attributes both mechanisms to MOR activity; benzodiazepines do not act at opioid receptors.
• Option B: Option B is incorrect because lorazepam and oxycodone do not share binding sites or compete at any receptor; lorazepam acts at GABA-A receptors and oxycodone at MOR, with no clinically meaningful competitive interaction between them.
• Option C: Option C is incorrect because lorazepam is not a CYP3A4 inhibitor and does not meaningfully alter oxycodone plasma concentrations through pharmacokinetic mechanisms; the interaction in this case is entirely pharmacodynamic.
• Option D: Option D is incorrect because lorazepam does not cause respiratory depression followed by secondary opioid accumulation — both agents produce respiratory depression simultaneously through their independent mechanisms, and reduced hepatic blood flow is not a clinically recognized mechanism of oxycodone accumulation.

ANSWER: B

Rationale:

Opioid-induced respiratory depression is mediated primarily through mu-opioid receptor (MOR) activation in brainstem respiratory control centers, particularly the pre-Bötzinger complex in the medulla, which functions as the central pattern generator for respiratory rhythm. MOR activation in these centers depresses the hypercapnic ventilatory drive — the critical reflex that increases respiratory rate and tidal volume in response to rising arterial carbon dioxide (CO₂) tension. This is the dominant mechanism: in patients with opioid-induced respiratory depression, arterial CO₂ rises progressively because the respiratory control system no longer responds appropriately to the hypercapnia signal, producing a slow, deep, irregular breathing pattern rather than the rapid shallow breathing seen in mechanically obstructed patients.

• Option A: Option A is incorrect because opioid-induced respiratory depression is a central nervous system (CNS) phenomenon — peripheral MOR activation at the neuromuscular junction does not produce respiratory muscle spasm; neuromuscular blockade-type effects are not part of the opioid pharmacological profile.
• Option C: Option C is incorrect because opioids do cause direct, sedation-independent depression of brainstem respiratory centers; patients can be apneic or severely hypoventilating while still responding to verbal stimuli — the respiratory depression is not merely a consequence of reduced consciousness.
• Option D: Option D is incorrect because opioids act at MOR, not GABA-A receptors; the GABA-A mechanism is the mechanism of benzodiazepines and barbiturates.
• Option E: Option E is incorrect because opioids impair both the hypercapnic (central) and hypoxic (peripheral chemoreceptor) ventilatory responses; the hypercapnic drive suppression is the dominant mechanism, and Option E incorrectly inverts which drive is affected.

ANSWER: C

Rationale:

When co-prescribing opioids and benzodiazepines is clinically unavoidable — for example, in a patient with both chronic pain requiring opioid therapy and a genuine anxiety disorder requiring benzodiazepine treatment — the correct approach is to use both agents at the lowest effective doses, with close monitoring, and to prescribe naloxone to the patient and a family member with explicit education on overdose recognition and response. The 2022 CDC (Centers for Disease Control and Prevention) Clinical Practice Guideline for Prescribing Opioids for Pain explicitly endorses naloxone co-prescribing in this setting. Home naloxone is effective for opioid-benzodiazepine combined overdose; while naloxone reverses the opioid component of respiratory depression but not the benzodiazepine component, even partial reversal of respiratory depression is often sufficient to restore consciousness and self-protective airway reflexes long enough for emergency services to arrive.

• Option A: Option A is incorrect because there is no evidence that a fixed 50% opioid dose reduction is the appropriate response, and arbitrarily reducing opioid therapy risks undertreating established chronic pain; the clinical decision requires individualized assessment of both agents, not a formulaic trade-off.
• Option B: Option B is incorrect because tramadol does not have a clinically meaningful ceiling effect on respiratory depression at the doses used in clinical practice; furthermore, tramadol carries its own serious serotonergic interaction risks that may be relevant in a patient with anxiety (who may be on or considered for SSRIs).
• Option D: Option D is incorrect because respiratory stimulants such as caffeine or theophylline are not accepted clinical tools for managing opioid-benzodiazepine respiratory depression risk; they are not part of any evidence-based guideline for this indication.
• Option E: Option E is incorrect on two counts: monthly monitoring alone is inadequate given the potential for acute respiratory events between visits, and the claim that home naloxone is ineffective for this combination is false — naloxone is recommended precisely for this scenario.

ANSWER: C

Rationale:

Gabapentinoids — gabapentin and pregabalin — have emerged as a clinically important contributor to opioid-related respiratory depression through inhibition of voltage-gated calcium channels (specifically the α2δ-1 subunit) in brainstem respiratory neurons, reducing excitatory neurotransmission in circuits essential for respiratory rhythmogenesis. Observational data have demonstrated that the combination of opioids with gabapentinoids significantly increases the risk of opioid-related mortality, prompting regulatory advisories and clinical guideline updates. In a patient already on the high-risk opioid-benzodiazepine combination, adding a gabapentinoid introduces a third independent mechanism of respiratory depression, warranting the same level of caution as the original combination. This triple combination — opioid plus benzodiazepine plus gabapentinoid — is recognized as a particularly high-risk polypharmacy pattern.

• Option A: Option A is incorrect because gabapentin does have central nervous system (CNS) depressant activity and does contribute to respiratory depression through its brainstem calcium channel inhibitory effects; the claim of exclusively peripheral sensory neuron activity is pharmacologically inaccurate.
• Option B: Option B is incorrect because gabapentin does not act at GABA-A receptors despite its name — it was named for its structural resemblance to GABA (gamma-aminobutyric acid), not its mechanism; gabapentin's mechanism is calcium channel inhibition, not GABA receptor modulation.
• Option D: Option D is incorrect because gabapentin is not metabolized by CYP3A4 — it is eliminated renally without significant hepatic metabolism, and does not inhibit CYP enzymes; it cannot increase oxycodone plasma concentrations through pharmacokinetic inhibition.
• Option E: Option E is incorrect because gabapentin and benzodiazepines are not pharmacodynamically interchangeable and act through distinct mechanisms; halving the benzodiazepine dose does not provide a validated or guideline-endorsed approach to managing the added risk from gabapentinoid co-administration.

ANSWER: D

Rationale:

Tramadol is unique among opioid analgesics in having clinically significant serotonin reuptake inhibitory activity, mediated through the parent compound (not its metabolites) acting on the serotonin transporter (SERT) in a manner analogous to a selective serotonin reuptake inhibitor (SSRI). When tramadol is co-administered with paroxetine, an SSRI, the combined serotonin reuptake inhibition produces excess synaptic serotonin accumulation, precipitating serotonin syndrome. The syndrome is defined by the classic triad of mental status changes (agitation, confusion), autonomic instability (hyperthermia, tachycardia, diaphoresis, hypertension), and neuromuscular abnormalities (clonus, hyperreflexia, tremor), all of which are present in this patient. The presentation is the diagnostic signature of serotonin toxicity, not opioid excess or another toxidrome. Option C is also mechanistically accurate but overly complex as written — it conflates the CYP2D6 metabolite explanation with the serotonergic mechanism; the serotonin syndrome in this case is driven by tramadol's SSRI-like serotonin reuptake inhibition interacting with paroxetine, and Option D captures this most cleanly and correctly.

• Option A: Option A is incorrect because tramadol does not cause serotonin syndrome through 5-HT3 receptor activation — 5-HT3 receptors mediate nausea and vomiting (relevant to the chemoreceptor trigger zone), not the autonomic and neuromuscular features of serotonin syndrome, which are mediated primarily through 5-HT2A receptor activation.
• Option B: Option B is incorrect in its conclusion: while paroxetine does inhibit CYP2D6 (cytochrome P450 2D6) and would reduce O-desmethyltramadol (M1) formation rather than increase it, M1 accumulation is not the mechanism of serotonin syndrome — excessive MOR (mu-opioid receptor) activation would produce miosis, respiratory depression, and sedation, not clonus and hyperthermia.
• Option E: Option E is incorrect because tramadol's active metabolite does not competitively displace paroxetine from SERT binding sites, and "SERT hyperactivation" is not a recognized mechanism of serotonin toxicity; serotonin syndrome results from excess serotonergic activity, not from transporter overactivation.

ANSWER: B

Rationale:

Serotonin syndrome is defined by the classic triad of (1) mental status changes — ranging from agitation, anxiety, and confusion to frank delirium; (2) autonomic instability — encompassing hyperthermia, tachycardia, diaphoresis, and hypertension (or hypotension in severe cases); and (3) neuromuscular abnormalities — most specifically clonus (particularly ankle clonus and inducible clonus), hyperreflexia, tremor, and myoclonus. All three components of the triad are represented in this patient's presentation: agitation (mental status), temperature of 38.9°C, heart rate of 118, diaphoresis, and hypertension (autonomic), and bilateral ankle clonus with hyperreflexia (neuromuscular). The Hunter Serotonin Toxicity Criteria use clonus as the most discriminating finding, and its presence with a serotonergic drug exposure meets diagnostic criteria.

• Option A: Option A is incorrect because it describes neuroleptic malignant syndrome (NMS), not serotonin syndrome; NMS is characterized by hyperthermia, lead-pipe rigidity, elevated creatine kinase (CK), and autonomic instability driven by dopamine D2 receptor blockade — not serotonergic excess. The key differentiating neuromuscular features are: serotonin syndrome = clonus and hyperreflexia; NMS = rigidity and hyporeflexia.
• Option C: Option C is incorrect because it describes the opioid toxidrome (miosis, respiratory depression, reduced consciousness), which is not the presentation here; this patient has hyperthermia, agitation, and hyperreflexia — none of which are features of opioid excess.
• Option D: Option D is incorrect because it describes the anticholinergic toxidrome (confusion, dry flushed skin, urinary retention, tachycardia, mydriasis); tramadol does not produce significant muscarinic receptor blockade at clinical doses, and the clinical picture is inconsistent with anticholinergic toxicity.
• Option E: Option E is incorrect because it describes the clinical picture of opioid excess from MOR hyperactivation — bradycardia, hypotension, sedation — which is opposite to the agitated, hyperthermic, hyperreflexic presentation of serotonin syndrome.

ANSWER: E

Rationale:

Clonus — particularly inducible ankle clonus, spontaneous clonus at the ankles or elsewhere, and ocular clonus (nystagmus-like oscillations) — is the neuromuscular finding most characteristic of and specific to serotonin syndrome. It arises from 5-HT2A receptor-mediated excitation of spinal motor circuits, producing rhythmic, involuntary oscillatory contractions. The Hunter Serotonin Toxicity Criteria identify clonus as the central diagnostic feature: spontaneous clonus alone is sufficient to meet Hunter criteria in the context of serotonergic drug exposure. In neuroleptic malignant syndrome (NMS), the neuromuscular picture is dominated by lead-pipe rigidity and hyporeflexia, not clonus; NMS reflects dopamine D2 receptor blockade-induced loss of inhibitory control of the extrapyramidal motor system. In anticholinergic toxidrome, there is no clonus — the neuromuscular findings are generally limited to mild tremor, and the presentation is dominated by dry flushed skin, mydriasis, urinary retention, and ileus.

• Option A: Option A is incorrect because hyperthermia does occur in all three syndromes but this answer misstates the key differentiator; while onset speed differs (serotonin syndrome tends to be faster), the most reliable distinguishing sign at the bedside is the neuromuscular examination, specifically clonus.
• Option B: Option B is incorrect because diaphoresis and tachycardia occur in all three toxidromes to varying degrees and are not pathognomonic for serotonin syndrome; they are features of autonomic instability shared across hyperadrenergic states.
• Option C: Option C is incorrect because while pupil changes (mild mydriasis) may be seen in serotonin syndrome, mydriasis is not pathognomonic and is also a cardinal feature of anticholinergic toxidrome — making it useless as a differentiating criterion between the two.
• Option D: Option D is incorrect because bradypnea and miosis are features of opioid toxicity, not serotonin syndrome; this patient's presentation is not consistent with opioid excess and these findings would point away from serotonin syndrome.

ANSWER: A

Rationale:

CYP2D6 ultrarapid metabolizers carry multiple functional copies of the CYP2D6 gene and convert tramadol to its active metabolite O-desmethyltramadol (M1) far more rapidly and completely than normal metabolizers. M1 is well established as a potent mu-opioid receptor (MOR) agonist — this is why codeine toxicity in ultrarapid metabolizers (neonatal deaths from nursing mothers) prompted the FDA black-box warning restricting codeine in this population. Less appreciated but clinically relevant, M1 also possesses weak serotonin reuptake inhibitory properties. At the excess M1 concentrations generated by ultrarapid CYP2D6 metabolism, this serotonergic activity can be sufficient to produce serotonin syndrome without a second serotonergic drug — particularly at the upper end of standard tramadol dosing, when very high M1 levels are reached rapidly. This explains why serotonin syndrome has been reported in CYP2D6 ultrarapid metabolizers on tramadol monotherapy.

• Option B: Option B is incorrect because CYP2D6 ultrarapid metabolizers do not produce excess parent tramadol — they convert tramadol to M1 more efficiently; it is CYP2D6 poor metabolizers (or patients on CYP2D6 inhibitors such as paroxetine) who have elevated parent tramadol concentrations.
• Option C: Option C is incorrect because SERT expression is not regulated by CYP2D6 genotype, and there is no established mechanism by which the ultrarapid metabolizer phenotype produces SERT hypersensitivity.
• Option D: Option D is incorrect because tramadol is not converted to a serotonin-releasing compound by CYP2D6 — the CYP2D6 metabolic product is M1, an MOR agonist, not an amphetamine-like releaser; the mechanism of action of MDMA (3,4-methylenedioxymethamphetamine) involves active serotonin release, which is distinct from reuptake inhibition.
• Option E: Option E is incorrect because CYP2D6 ultrarapid metabolizer status does not cause compensatory upregulation of CYP3A4, and no serotonergic tramadol metabolite uniquely generated by CYP3A4 in ultrarapid metabolizers has been identified.

ANSWER: C

Rationale:

There are two distinct types of opioid-MAOI interactions, and correctly identifying which applies to meperidine is clinically critical. The excitatory or serotonergic reaction occurs specifically with meperidine (and to a lesser extent tramadol, fentanyl, and methadone): meperidine inhibits neuronal serotonin reuptake through an SSRI-like mechanism. When combined with an irreversible MAOI such as phenelzine — which prevents serotonin catabolism by blocking monoamine oxidase — the resulting excess synaptic serotonin produces acute serotonin toxicity. The clinical presentation is exactly what is described: hyperthermia, agitation, diaphoresis, clonus, hyperreflexia, tachycardia, and hypertension — the hallmarks of serotonin syndrome. This reaction has been fatal, and the meperidine-MAOI combination is absolutely contraindicated. The second type of reaction (the depressive or potentiation reaction) occurs with morphine and most full MOR agonists that lack serotonergic activity — MAOIs impair their hepatic metabolism, producing elevated opioid concentrations and respiratory depression; this is the reaction described in Option A.

• Option A: Option A is incorrect as applied to this patient because the depressive-potentiation reaction does not produce the excitatory syndrome — hyperthermia, agitation, and clonus — seen here; it produces sedation and respiratory depression.
• Option B: Option B is incorrect because phenelzine does not irreversibly inhibit CYP2D6 — MAOIs inhibit monoamine oxidase enzymes (MAO-A and MAO-B), not CYP450 enzymes; normeperidine accumulation is a separate toxicity concern unrelated to MAOI co-administration.
• Option D: Option D is incorrect because phenelzine does not exert clinically meaningful alpha-2 adrenergic blocking activity, and meperidine's primary receptor activity is at the mu-opioid receptor rather than kappa-opioid receptors in the relevant clinical sense.
• Option E: Option E is incorrect because the meperidine-MAOI interaction is not a hypersensitivity or immune-mediated reaction; it is a direct pharmacodynamic interaction through serotonergic mechanisms.

ANSWER: B

Rationale:

The meperidine-MAOI interaction is one of the most severe and well-documented absolute contraindications in clinical pharmacology. Meperidine is absolutely contraindicated in patients receiving any MAOI — whether irreversible (phenelzine, tranylcypromine, isocarboxazid) or reversible (moclobemide) — because the excitatory serotonergic reaction has caused death and carries no established safe dose threshold. Fatal reactions have been reported with meperidine doses as low as a single standard analgesic dose in MAOI-treated patients. The contraindication extends across all doses, all routes, and both reversible and irreversible MAOIs. Because irreversible MAOIs require approximately 14 days for MAO enzyme activity to regenerate after discontinuation, the contraindication persists for two weeks after stopping an irreversible MAOI; for reversible MAOIs, the washout period is shorter (approximately 48–72 hours for moclobemide).

• Option A: Option A is incorrect because no safe low-dose threshold for meperidine in MAOI patients has been established; the absolute nature of this contraindication specifically means that dose reduction does not provide a clinically reliable safety margin, and the presence of cyproheptadine on standby does not constitute an adequate safeguard against a potentially fatal interaction.
• Option C: Option C is incorrect because meperidine is contraindicated with all MAOIs including reversible ones; the reversible-versus-irreversible distinction affects the duration of the washout period but does not create a class of "safe MAOI" with which meperidine can be used — and a 7-day washout is insufficient for irreversible MAOIs, which require 14 days.
• Option D: Option D is incorrect because the meperidine-MAOI excitatory reaction is not dependent on CYP2D6 phenotype; the interaction is pharmacodynamic (serotonergic) and occurs regardless of CYP2D6 metabolizer status.
• Option E: Option E is incorrect because the dose threshold claim is not supported by clinical or pharmacological evidence; the absolute contraindication applies regardless of dose or indication.

ANSWER: D

Rationale:

When opioid analgesia is required in a patient on an irreversible MAOI, the critical pharmacological distinction is between the excitatory serotonergic reaction (meperidine, tramadol, and to a lesser extent fentanyl and methadone — carry serotonin reuptake inhibitory activity) and the depressive or potentiation reaction (morphine and most other full MOR agonists without significant serotonergic activity — carry risk of elevated opioid concentrations due to MAOI inhibition of hepatic oxidative metabolism). Morphine produces the depressive-potentiation type of MAOI interaction, which, while clinically significant and requiring careful dose reduction and monitoring, is predictable, dose-related, and manageable. It does not carry the unpredictable, potentially fatal excitatory reaction seen with meperidine. Morphine is therefore preferred over meperidine, tramadol, or agents with serotonergic activity in a patient who must receive an opioid while on MAOI therapy.

• Option A: Option A is incorrect because tramadol is at least as dangerous as meperidine in MAOI-treated patients due to its potent serotonin reuptake inhibitory activity; shorter half-life does not reduce the severity of the acute serotonergic reaction, and tramadol-MAOI combinations are absolutely contraindicated.
• Option B: Option B is incorrect because codeine's conversion to morphine by CYP2D6 does not make it inherently safe with MAOIs — it also has some serotonergic activity, and more importantly, codeine itself can contribute to serotonin syndrome in MAOI-treated patients; it is not the preferred choice.
• Option C: Option C is incorrect because fentanyl, while having lower serotonergic activity than meperidine or tramadol, is not the classic first-line preferred opioid in the MAOI-treated patient — morphine is the better-characterized choice for this specific clinical scenario; fentanyl does carry some serotonergic risk and the potentiation risk at high doses.
• Option E: Option E is incorrect because oxycodone is not exclusively CYP3A4-metabolized — CYP2D6 contributes to its metabolism, and more critically, oxycodone is not identified in the pharmacological literature as free of MAOI interaction risk; the claim that no dose adjustment is required is unsupported.

ANSWER: E

Rationale:

Linezolid, although developed as an oxazolidinone antibiotic, possesses reversible, non-selective monoamine oxidase inhibitory activity as an off-target pharmacological property. This MAOI activity is clinically significant: linezolid has been implicated in serotonin syndrome when combined with serotonergic drugs including meperidine, tramadol, and serotonergic antidepressants (SSRIs, SNRIs). The FDA prescribing information for linezolid includes warnings about serotonin syndrome risk with serotonergic drugs, and clinical cases of fatal serotonin syndrome from linezolid combined with serotonergic opioids are documented in the literature. Clinicians must screen for linezolid use — just as they would for traditional MAOIs — when prescribing meperidine, tramadol, or other serotonergic opioids, because linezolid's widespread use as an antibiotic makes this combination a realistic clinical risk. Option B is also pharmacologically accurate in most respects but slightly overstates certainty around the 48–72 hour washout as the established clinical standard; Option E is the more precisely calibrated correct answer for examination purposes as it captures the key clinical point without overspecifying the washout timeline.

• Option A: Option A is incorrect because linezolid's mechanism of antibiotic action (50S ribosomal subunit inhibition in bacteria) is indeed separate from its mammalian MAOI activity, but the absence of mechanistic overlap does not eliminate the off-target MAOI effect — both properties are present simultaneously; Option A conflates linezolid's antibacterial target with its systemic pharmacology.
• Option C: Option C is incorrect because linezolid is a reversible, non-selective MAO inhibitor — not an irreversible MAO-B selective inhibitor; and there is no dose threshold above which it becomes a MAOI (the MAOI activity is present at standard antibiotic doses).
• Option D: Option D is incorrect because linezolid's MAOI activity is clinically meaningful without requiring a second serotonergic agent as a co-trigger; it acts as a functional MAOI at standard antibiotic doses and does not require synergistic amplification.

ANSWER: E

Rationale:

Fentanyl is almost entirely dependent on CYP3A4 (cytochrome P450 3A4) for its hepatic metabolism to inactive norfentanyl and other metabolites. Fluconazole is a potent, broad-spectrum azole antifungal that inhibits CYP3A4 (as well as CYP2C9 and other enzymes) through tight binding of its triazole nitrogen to the heme iron of the CYP enzyme active site. When CYP3A4 activity is substantially reduced by fluconazole, fentanyl's hepatic clearance falls dramatically, and plasma fentanyl concentrations rise progressively — even though the transdermal delivery rate from the patch itself is unchanged. The time course of 24–48 hours to clinical toxicity reflects the gradual accumulation as fentanyl input continues at the same rate while output via metabolism is impaired. This interaction is clinically well recognized and requires either a dose reduction of the transdermal fentanyl patch or substitution of a non-CYP3A4-dependent opioid when strong CYP3A4 inhibitors are necessary.

• Option A: Option A is incorrect because fluconazole has no direct MOR agonist activity and no pharmacodynamic interaction with opioid receptors; its entire clinical effect in this interaction is pharmacokinetic.
• Option B: Option B is incorrect because fluconazole inhibits, rather than induces, CYP3A4; and fentanyl's primary metabolite norfentanyl is inactive — there is no more potent fentanyl metabolite whose accumulation drives toxicity.
• Option C: Option C is incorrect because fluconazole does not significantly displace fentanyl from plasma protein binding; the protein displacement mechanism, while pharmacologically real for some drug pairs, is not the operative mechanism in the fentanyl-fluconazole interaction.
• Option D: Option D is incorrect because fluconazole's antifungal mechanism (ergosterol synthesis inhibition via CYP51 in fungi) does not impair mammalian hepatic blood flow; any effect on fentanyl clearance is mediated through CYP enzyme inhibition, not hemodynamic changes.

ANSWER: C

Rationale:

Methadone is unique among opioid analgesics in carrying clinically significant QTc prolongation risk through blockade of cardiac hERG (human ether-à-go-go related gene) potassium channels — the channels responsible for the rapid delayed rectifier potassium current (IKr) that contributes to cardiac repolarization. QTc prolongation from methadone is concentration-dependent, meaning that any factor that raises methadone plasma concentrations also increases the degree of QTc prolongation. CYP3A4 inhibition by fluconazole reduces methadone's hepatic clearance and raises plasma methadone concentrations — which in this patient who is already on a stable methadone dose may tip the QTc from borderline prolongation into the dangerous range for torsades de pointes (TdP), a potentially fatal ventricular arrhythmia. This dual risk — opioid toxicity from elevated concentrations plus QTc-mediated arrhythmia risk — makes the fluconazole-methadone interaction substantially more dangerous than the fluconazole-fentanyl interaction, where QTc effects are not a primary concern.

• Option A: Option A is incorrect because methadone undergoes significant hepatic CYP3A4-mediated metabolism, not primarily renal elimination; CYP3A4 inhibition by fluconazole does reduce methadone clearance.
• Option B: Option B is incorrect because methadone does not allosterically activate CYP3A4 — no such drug-enzyme interaction has been established; CYP3A4 inhibition by fluconazole is consistent across substrates.
• Option D: Option D is incorrect because methadone does not have a recognized hepatotoxic active metabolite, and the "progressive feedback loop" mechanism described is not pharmacologically established for this drug combination.
• Option E: Option E is incorrect because methadone does not act as a 5-HT2A receptor agonist, and fluconazole does not inhibit SERT; neither of these mechanisms applies to the drugs in question, and serotonin syndrome is not the relevant interaction concern here.

ANSWER: B

Rationale:

Among the macrolide antibiotics, there is a clinically critical distinction in CYP3A4 inhibitory activity: clarithromycin and erythromycin are strong CYP3A4 inhibitors through a mechanism-based inactivation (suicide inhibition) pathway, in which their nitrosoalkane metabolite forms a stable, inhibitory complex with the CYP3A4 heme iron. Azithromycin, a 15-membered azalide macrolide, does not form this inhibitory metabolite and does not significantly inhibit CYP3A4 at standard clinical doses. This pharmacokinetic distinction is clinically important: azithromycin can generally be used in patients on CYP3A4-dependent opioids such as fentanyl, methadone, or buprenorphine without the drug interaction concern that applies to clarithromycin or erythromycin. The prescribing hospitalist's choice of azithromycin — rather than clarithromycin — for this patient on fentanyl was therefore pharmacologically appropriate.

• Option A: Option A is incorrect because it conflates azithromycin with clarithromycin; azithromycin does not significantly inhibit CYP3A4 and does not require fentanyl dose reduction.
• Option C: Option C is incorrect because azithromycin does not inhibit CYP3A4 at all through competitive substrate inhibition — the distinction is not mechanism but rather the absence of meaningful inhibitory activity in azithromycin versus the potent mechanism-based inhibition of clarithromycin and erythromycin.
• Option D: Option D is incorrect because shared macrolactone ring structure does not confer identical CYP3A4 inhibitory activity; azithromycin's structural difference (15-membered azalide ring with a nitrogen insertion, versus the 14-membered rings of erythromycin and clarithromycin) results in a fundamentally different metabolic profile.
• Option E: Option E is incorrect because azithromycin is neither a meaningful CYP3A4 inducer nor an inhibitor; it does not significantly alter CYP3A4 activity in either direction at therapeutic doses.

ANSWER: D

Rationale:

When a strong CYP3A4 inhibitor such as fluconazole is necessary and cannot be substituted, the correct pharmacological approach is to switch the CYP3A4-dependent opioid to one whose clearance does not depend on CYP3A4. Hydromorphone is an excellent choice in this context: it is primarily metabolized by UDP-glucuronosyltransferase (UGT) enzymes to hydromorphone-3-glucuronide rather than by CYP3A4, and its clearance is therefore not significantly affected by fluconazole co-administration. The transition from transdermal fentanyl to hydromorphone requires a careful equianalgesic dose conversion (with the standard 25–50% reduction for incomplete cross-tolerance), and oxymorphone is another glucuronidation-dependent alternative. This approach addresses the root cause — the CYP3A4-mediated reduction in fentanyl clearance — by eliminating the CYP3A4-dependent substrate while allowing full-dose fluconazole to continue treating the esophageal candidiasis.

• Option A: Option A is incorrect because scheduled oral naloxone at low doses is a strategy used in combination opioid-naloxone formulations to limit peripheral opioid-induced constipation, not a tool for managing CYP3A4 interaction-mediated opioid toxicity; it does not address rising fentanyl concentrations and carries risk of precipitating pain crisis or opioid withdrawal.
• Option B: Option B is incorrect because 50 mg daily is below the standard therapeutic dose for esophageal candidiasis (which requires 200–400 mg/day), and fluconazole inhibits CYP enzymes across all therapeutic doses — there is no established low-dose threshold at which clinically significant CYP3A4 inhibition disappears.
• Option C: Option C is incorrect because voriconazole is itself a potent inhibitor of CYP3A4, CYP2C9, and CYP2C19; switching from fluconazole to voriconazole does not eliminate the CYP3A4 interaction with fentanyl and may worsen it.
• Option E: Option E is incorrect because sustained CYP3A4 inhibition by fluconazole does not induce compensatory CYP3A4 downregulation — fluconazole produces stable, persistent enzyme inhibition throughout its therapeutic use; there is no pharmacological adaptive mechanism that restores CYP3A4 activity to baseline while fluconazole inhibition continues.

ANSWER: D

Rationale:

Rifampin is one of the most potent inducers of drug-metabolizing enzymes in clinical use. It activates the pregnane X receptor (PXR), a nuclear receptor that transcriptionally upregulates CYP3A4 (cytochrome P450 3A4), CYP2C9, CYP2C19, CYP1A2, and the drug efflux transporter P-glycoprotein (P-gp). Methadone is substantially CYP3A4-dependent for its hepatic metabolism; rifampin-induced CYP3A4 upregulation dramatically accelerates methadone clearance, producing a large and rapid fall in methadone plasma concentrations. In a patient who is physically dependent on methadone, this pharmacokinetically induced concentration drop precipitates opioid withdrawal — even though the prescribed methadone dose is unchanged — because the effective plasma methadone level has fallen below the concentration required to occupy sufficient MOR to suppress the withdrawal syndrome. Clinical reports document that rifampin co-administration with methadone has required dose increases of 50% or more to control withdrawal, with some patients requiring dose doubling.

• Option A: Option A is incorrect because isoniazid does have modest MAO inhibitory activity, but this does not produce methadone toxicity in this clinical setting — the temporal course and symptom complex are classic opioid withdrawal driven by rifampin-induced CYP3A4 induction, not MAOI-mediated toxicity.
• Option B: Option B is incorrect because pyrazinamide does not alkalinize urine — it can cause mild urine acidification through urate metabolism effects — and renal tubular excretion of methadone is not a primary elimination pathway; pH-mediated changes would not produce the rapid, severe withdrawal seen here.
• Option C: Option C is incorrect because ethambutol acts by inhibiting mycobacterial arabinosyltransferase (an enzyme involved in mycobacterial cell wall synthesis) and does not chelate zinc ions at mammalian CYP enzyme active sites; ethambutol has no clinically meaningful effect on methadone metabolism.
• Option E: Option E is incorrect because rifampin has no binding affinity for mu-opioid receptors and does not displace methadone through receptor competition; rifampin's entire clinical effect on methadone is pharmacokinetic — mediated through CYP enzyme induction — not through receptor-level pharmacodynamic antagonism.

ANSWER: C

Rationale:

When rifampin is required in a methadone-maintained patient and cannot be substituted, the clinical approach is to increase the methadone dose — incrementally and with monitoring — until withdrawal symptoms are suppressed. Published case series and clinical guidelines document that dose increases of 50% or more are commonly required during rifampin co-administration; in some patients, dose doubling has been necessary. Because rifampin produces stable CYP3A4 induction throughout the course of TB treatment (typically six months), the elevated methadone dose must be maintained for the full rifampin treatment duration. Critically, when rifampin is eventually discontinued, the CYP3A4 induction resolves over approximately two weeks, and methadone plasma concentrations will rise progressively as clearance falls back toward baseline — placing the patient at risk for opioid toxicity if the elevated dose is maintained. The methadone dose must therefore be reduced proactively as rifampin is stopped.

• Option A: Option A is incorrect because buprenorphine is also substantially CYP3A4-dependent in its metabolism and is also subject to rifampin-induced induction; switching to buprenorphine does not eliminate the drug interaction problem, and the "no washout period" claim is incorrect — buprenorphine initiation after methadone requires careful timing to avoid precipitated withdrawal.
• Option B: Option B is incorrect because adding a benzodiazepine without addressing the underlying methadone deficiency treats only symptoms while leaving the patient in a medically unstable state; moreover, opioid-benzodiazepine co-administration carries its own serious respiratory depression risks, particularly in a patient whose methadone level is being actively managed.
• Option D: Option D is incorrect because morphine is not fully exempt from rifampin induction effects — while morphine's primary pathway is glucuronidation, rifampin also induces UGT enzymes and P-glycoprotein, and substantial morphine dose adjustments may still be needed; the claim that morphine can be maintained at the current dose without adjustment is inaccurate.
• Option E: Option E is incorrect because clonidine is an alpha-2 adrenergic receptor agonist that acts at presynaptic locus coeruleus neurons to reduce noradrenergic outflow — the central mechanism of many opioid withdrawal symptoms; it is not a partial MOR agonist. Clonidine can provide symptomatic relief of some withdrawal features but does not replace opioid receptor occupancy and is not an adequate standalone management strategy for maintaining opioid dependence during induced subtherapeutic methadone levels.

ANSWER: B

Rationale:

CYP3A4 induction is mediated primarily through nuclear receptors — most importantly the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) — that, when activated by inducing drugs, transcriptionally upregulate CYP3A4, other CYP isoforms, and drug transporters such as P-glycoprotein (P-gp). The clinically most important CYP3A4 inducers in the context of opioid drug interactions are anticonvulsants (carbamazepine, phenytoin, phenobarbital), the herbal supplement St. John's wort (hypericin and hyperforin as PXR activators), and antiretrovirals in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class (efavirenz, nevirapine). All of these are potent CYP3A4 inducers capable of producing the same type and magnitude of methadone-withdrawal interaction as rifampin. Patients on methadone maintenance therapy (MMT) who are prescribed any of these agents require close monitoring and likely dose escalation.

• Option A: Option A is incorrect because fluconazole, clarithromycin, ritonavir, and grapefruit juice are all CYP3A4 inhibitors, not inducers — they elevate, rather than reduce, opioid plasma concentrations; the PXR induction mechanism stated in Option A does not apply to these agents.
• Option C: Option C is incorrect because haloperidol, lithium, valproate, and gabapentin are not clinically significant CYP3A4 inducers; gabapentin is renally eliminated without significant CYP metabolism, and none of the others in this list produce meaningful CYP3A4 induction at therapeutic doses.
• Option D: Option D is incorrect because metronidazole, fluconazole, and voriconazole are all CYP inhibitors (not inducers) — fluconazole and voriconazole inhibit CYP3A4, and metronidazole inhibits CYP2C9; none of these upregulate CYP3A4 expression.
• Option E: Option E is incorrect because while glucocorticoids (including dexamethasone) can activate PXR and induce CYP3A4, this is not through direct GRE activation exclusively; spironolactone and progesterone have modest PXR-activating properties but are not established as clinically significant CYP3A4 inducers requiring opioid dose adjustments in practice, and the mechanistic claim in Option E is pharmacologically oversimplified.

ANSWER: B

Rationale:

Rifampin induces CYP3A4 by activating the pregnane X receptor (PXR), which upregulates transcription of the CYP3A4 gene. This is a reversible process: once rifampin is discontinued, PXR activation ceases and CYP3A4 protein levels return toward baseline as existing (induced) enzyme molecules are degraded through normal protein turnover. The time course for this reversal is approximately two weeks — consistent with the half-life of the CYP3A4 enzyme protein and the time required for PXR-mediated transcriptional induction to dissipate. During this two-week period, CYP3A4-mediated methadone metabolism progressively decreases, and methadone plasma concentrations rise progressively from the induced (low) level back toward the pre-rifampin level. In a patient whose methadone dose was increased by 50% or more to compensate for rifampin induction, this rising concentration carries a real risk of opioid toxicity — including respiratory depression — if the dose is not proactively reduced. The correct approach is to begin gradual methadone dose reduction starting at or shortly after rifampin discontinuation, with close clinical monitoring and ideally plasma methadone level measurements.

• Option A: Option A is incorrect because CYP3A4 induction by rifampin is not competitive-reversible in the pharmacological sense — it is transcriptional induction of enzyme protein synthesis; resolution requires protein turnover over approximately two weeks, not rapid dissipation within 24–48 hours. An immediate dose reduction on day 1 of rifampin discontinuation may be premature and underestimate the pace of the change.
• Option C: Option C is incorrect because MOR downregulation from chronic opioid exposure is not irreversible; opioid tolerance and receptor downregulation resolve over days to weeks following dose reduction, and there is no clinical basis for permanently maintaining an elevated methadone dose after the pharmacokinetic reason for it (rifampin induction) has resolved.
• Option D: Option D is incorrect because rifampin-induced CYP3A4 upregulation is not permanent — it is transcriptionally reversible, and CYP3A4 expression returns to the patient's genetic baseline once rifampin is cleared.
• Option E: Option E is incorrect because no pharmacological rebound CYP3A4 suppression below baseline has been established following rifampin discontinuation; there is no overshoot phenomenon, and the methadone dose does not need to fall below the original pre-rifampin level under normal circumstances.

ANSWER: D

Rationale:

Codeine is a classic opioid prodrug with very low intrinsic affinity for the mu-opioid receptor (MOR); its analgesic effect depends almost entirely on CYP2D6 (cytochrome P450 2D6)-mediated O-demethylation to morphine. Fluoxetine is one of the most potent inhibitors of CYP2D6 in clinical use. By blocking CYP2D6, fluoxetine dramatically reduces codeine-to-morphine conversion: the patient accumulates parent codeine (which provides little analgesia at MOR) while generating insufficient morphine (the active analgesic metabolite). The result is analgesic failure despite full prescribed codeine dosing. This interaction is a well-documented clinical consequence of combining codeine with CYP2D6 inhibitors, and is one of the principal reasons codeine is problematic in patients on fluoxetine, paroxetine, or other strong CYP2D6 inhibitors.

• Option A: Option A is incorrect because codeine's metabolic activation to morphine is mediated by CYP2D6, not CYP3A4; the CYP3A4 pathway converts codeine to norcodeine, which is not an active analgesic. Fluoxetine also inhibits CYP2D6, not CYP3A4, so
• Option A: Option A misidentifies both the relevant enzyme and the inhibitor's target.
• Option B: Option B is incorrect because SSRI-mediated upregulation of spinal serotonin signaling does not produce clinically meaningful direct antagonism of opioid receptor analgesia; while serotonin participates in descending pain modulation, SSRI therapy does not substantially reduce the MOR-mediated analgesic response to opioids through a pharmacodynamic mechanism that accounts for complete analgesic failure.
• Option C: Option C is incorrect because fluoxetine has no binding affinity for MOR and does not competitively displace opioids from opioid receptors; its interaction with codeine is entirely pharmacokinetic (CYP2D6 inhibition), not pharmacodynamic receptor competition.
• Option E: Option E is incorrect because fluoxetine does not clinically inhibit hepatic P-glycoprotein (P-gp) in a manner that produces meaningful CNS exclusion of codeine; CNS penetration is not codeine's rate-limiting step for analgesia, and the P-gp/blood-brain barrier mechanism described in Option E is not a recognized clinical explanation for codeine analgesic failure.

ANSWER: C

Rationale:

Tramadol is not an appropriate substitute for codeine in this clinical context for two compounding reasons. First, tramadol, like codeine, requires CYP2D6 (cytochrome P450 2D6)-mediated O-demethylation for the formation of its primary opioid-active metabolite, O-desmethyltramadol (M1). M1 is a potent MOR agonist responsible for a substantial portion of tramadol's analgesic effect; CYP2D6 inhibition by fluoxetine would reduce M1 formation and impair tramadol's analgesic efficacy by the same mechanism that causes codeine failure — producing elevated parent tramadol with inadequate M1. Second, and critically for patient safety, tramadol has significant serotonin reuptake inhibitory activity through the parent compound. When combined with fluoxetine — itself an SSRI — the combined serotonergic load carries a clinically meaningful risk of serotonin syndrome, as seen in Case 3 of this series. Tramadol-SSRI combinations are a recognized cause of serotonin toxicity. For both pharmacokinetic and pharmacodynamic reasons, tramadol is the wrong choice in this patient.

• Option A: Option A is incorrect because tramadol is not a full MOR agonist independent of CYP2D6; the parent tramadol compound has weak MOR affinity and M1 formation is essential for meaningful MOR-mediated analgesia — the statement that tramadol's effect is entirely independent of CYP2D6 metabolism is pharmacologically false.
• Option B: Option B is incorrect and inverts the pharmacology: M1 is the MOR-active analgesic metabolite, not the serotonergic one; the parent tramadol compound carries the SSRI-like serotonin reuptake inhibitory activity. Reducing M1 formation through CYP2D6 inhibition reduces analgesia, not serotonergic risk.
• Option D: Option D is incorrect because tramadol's analgesic mechanism is dual — both MOR activation (via M1) and monoamine reuptake inhibition — and CYP2D6 status is directly relevant to the MOR component of analgesia; the claim that CYP2D6 is irrelevant to tramadol's clinical efficacy is false.
• Option E: Option E is incorrect because parent tramadol has substantially lower MOR affinity than M1; accumulation of parent tramadol under CYP2D6 inhibition does not produce enhanced MOR analgesia — it produces reduced analgesia from the opioid component alongside increased serotonergic activity from the parent compound.

ANSWER: E

Rationale:

Strong CYP2D6 inhibitors are distributed across multiple drug classes, not confined to SSRIs. The most clinically important potent CYP2D6 inhibitors include: paroxetine (SSRI — one of the most potent CYP2D6 inhibitors in clinical use, comparable to fluoxetine), bupropion (antidepressant/smoking cessation agent — potent CYP2D6 inhibitor despite its non-serotonergic mechanism), duloxetine (serotonin-norepinephrine reuptake inhibitor, SNRI — moderate-to-potent CYP2D6 inhibitor), and quinidine (antiarrhythmic — so potent a CYP2D6 inhibitor it has been used experimentally to phenocopy the CYP2D6 poor metabolizer state). Any of these agents, when co-prescribed with codeine or tramadol, would produce the same CYP2D6 inhibition-mediated analgesic failure. Clinicians prescribing codeine or tramadol must review the patient's full medication list for CYP2D6 inhibitors, not just SSRIs.

• Option A: Option A is incorrect because cimetidine is primarily a CYP3A4, CYP1A2, and CYP2C9 inhibitor — not a strong CYP2D6 inhibitor — and omeprazole and pantoprazole are not significant CYP2D6 inhibitors; their primary CYP inhibitory activity is at CYP2C19 (for omeprazole/pantoprazole). The proton pump inhibitor drug class does not inhibit CYP2D6 through an imidazole ring mechanism.
• Option B: Option B is incorrect because metformin, sitagliptin, and empagliflozin are antidiabetic agents with no clinically meaningful CYP2D6 inhibitory activity; metformin is eliminated renally without significant CYP metabolism, and the described mechanism of mitochondrial complex I inhibition leading to hepatic CYP inhibition does not translate into CYP2D6 inhibition relevant to opioid analgesic activation.
• Option C: Option C is incorrect because amiodarone is primarily a CYP2D6 inhibitor (a valid point), but digoxin is a P-glycoprotein substrate and not a CYP2D6 inhibitor, and diltiazem is primarily a CYP3A4 inhibitor rather than a CYP2D6 inhibitor; the group as stated is pharmacologically mixed and inaccurate as a class.
• Option D: Option D is incorrect because calcium channel blockers as a class are not strong CYP2D6 inhibitors; verapamil inhibits CYP3A4 and P-gp, and amlodipine and nifedipine have minimal CYP2D6 inhibitory activity; the claim that calcium channel blocker therapy requires routine codeine dose doubling is not supported by pharmacological evidence or clinical guidelines.

ANSWER: A

Rationale:

Hydromorphone and oxymorphone are direct MOR agonists that do not require CYP2D6-mediated metabolic activation to exert their analgesic effects — they are pharmacologically active in the form administered and are metabolized primarily by UDP-glucuronosyltransferase (UGT) enzymes to glucuronide conjugates rather than undergoing CYP2D6-dependent bioactivation. Fluoxetine's CYP2D6 inhibitory activity therefore does not impair their analgesic efficacy. Importantly, neither hydromorphone nor oxymorphone carries significant serotonin reuptake inhibitory activity, and neither poses meaningful serotonin syndrome risk when combined with fluoxetine. Hydromorphone in particular is a widely available, well-characterized opioid that is appropriate for this outpatient postoperative pain scenario.

• Option B: Option B is incorrect because CYP2D6 inhibition by fluoxetine is potent and concentration-dependent — doubling the codeine dose does not reliably overcome the enzymatic block; the inhibitor reduces CYP2D6 activity toward the poor metabolizer phenotype regardless of codeine dose, and dose escalation primarily increases parent codeine concentrations (and its associated CNS and gastrointestinal adverse effects) without proportionate morphine formation.
• Option C: Option C is incorrect because meperidine does carry clinically significant serotonin reuptake inhibitory activity, and its combination with SSRIs including fluoxetine carries a risk of serotonin syndrome through the same mechanism as the tramadol-SSRI interaction; meperidine is contraindicated or requires extreme caution in patients receiving serotonergic drugs.
• Option D: Option D is incorrect because methadone's analgesic mechanism is not primarily NMDA receptor antagonism — it is primarily MOR agonism; NMDA antagonism contributes to methadone's profile in neuropathic pain and tolerance reduction but does not make CYP2D6 status irrelevant to its efficacy, and more critically, methadone is an inappropriate choice for routine outpatient postoperative analgesia given its complex pharmacokinetics, variable equianalgesic ratio, QTc prolongation risk, and the specialized expertise required for safe dosing.
• Option E: Option E is incorrect because buprenorphine's partial agonist ceiling on respiratory depression is a property specific to its pharmacodynamic profile at MOR and does not render partial agonists immune to CYP2D6 effects; buprenorphine itself is substantially CYP3A4-dependent and subject to CYP interaction effects, though not via CYP2D6 in the same way as codeine. Buprenorphine is also not routinely used as a first-line postoperative analgesic in opioid-naive patients in this clinical context.